EGFR and cancer: So et al. could show that autophagosome-mediated EGFR down-regulation induced by the CK2-inhibitor CX-4945 enhanced the efficacy of EGFR-inhibitors on EGFR-mutant lung cancer cells with resistance to the EGFR-inhibitors gefitinib and erlotinib and effectively inhibited cancer-cell proliferation [85].